Neonatal and paediatric infection

Viral Hepatitis

Volumn , Issue , 2007, Pages 714-739

  Kelly, Deirdre ^a   Boxall, Elizabeth ^b  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Cytomegalovirus; Intrauterine infection; Neonatal viral hepatitis; Rubella virus; Toxoplasmosis

Indexed keywords

EID: 36448944839     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987131.ch47     Document Type: Chapter

References (259)

1. Bale JF Jr. Congenital infections. Neurol Clin 2002;20:1039-60.
2. Rahman MM. Khan AM, Hafiz MM et al. Congenital hearing impairment with rubella: lessons from Bangladesh. Southeast Asian J Trop Med Health 2002;33:811-17.
3. Forrest JM, Turnbull FM, Sholler GF et al. Gregg’s congenital rubella patients 60 years later. Med J Aust 2002;177:664-7.
4. Berge P, Stagno S, Federer W et al. Impact of asymptomatic congenital cytomegalovirus infection on size at birth and gestational duration. Pediatr Infect Dis J 1990;9:170-5.
5. Chang MH, Huang HH, Huang ES et al. Polymerase chain reaction to detect human cytomegalovirus in livers of infants with neonatal hepatitis. Gastroenterology 1992;103:1022-5.
6. Liu Z, Wang E, Taylor W et al. Prevalence survey of cytomegalovirus infection in children in Chengdu. Am J Epidemiol 1990;131:143-50.
7. Griffiths PD, Baboonian C, Rutter D, Peckham C. Congenital and maternal cytomegalovirus infections in a London population. Br J Obstet Gynaecol 1991;98:135-40.
8. Peckham CS. Cytomegalovirus infection: congenital and neonatal disease. Scand J Infect Dis 1991;80(Suppl.)):82-7.
9. Wu J, Tang ZY, Wu YX, Li WR. Acquired cytomegalovirus infection of breastmilk in infancy. Chin Med J 1989;102:124-8.
10. Hart MH, Kaufman SS, Vanderhoof JA et al. Neonatal hepatitis and extrahepatic biliary atresia associated with cytomegalovirus infection in twins. Am J Dis Child 1991;145:302-4.
11. Tarr PI, Haas JE, Christie DL. Biliary atresia, cytomegalovirus, and age at referral. Pediatrics 1996;97:828-31.
12. Giacchino R, Navone C, Ciravegna B et al. Liver cirrhosis in childhood. Considerations on 22 cases with different etiology. Pediatr Med Chir 1990;12:147-52.
13. Le Luyer B, Menager V, Le Roux P et al. Liver fibrosis after neonatal cytomegalovirus infection. Arch Fr Pediatr 1990;47:361-4.
14. Ghishan FK, Greene HL, Halter S, Barnard J, Moran JR. Noncirrhotic portal hypertension in congenital cytomegalovirus infection. Hepatology 1984;4:684-6.
15. Conboy TJ, Pass RF, Stagno S et al. Early clinical manifestations and intellectual outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr 1987;111:343-8.
16. Schultz DA, Chandler S. Cytomegalovirus testing: antibody determinations and viral cultures with recommendations for use. J Clin Lab Anal 1991;5:69-73.
17. Paya CV, Holley KE, Wiesner RH et al. Early diagnosis of cytomegalovirus hepatitis in liver transplant recipients: role of immunostaining, DNA hybridization and culture of hepatic tissue. Hepatology 1990;12:119-26.
18. Lurie M, Elmalach I, Schuger L, Weintraub Z. Liver findings in infantile cytomegalovirus infection: similarity to extrahepatic biliary obstruction. Histopathology 1987;11:1171-80.
19. Alford CA, Stagno S, pass RF, Britt WJ. Congenital and perinatal CMV infections. Rev Infect Dis 1990;12:5745-53.
20. Gershon AA. Viral vaccines of the future. Pediatr Clin North Am 1990;37:689-707.
21. Nigro G, Taliani G, Krzysztofiak A et al. Multiple viral infections in HIV-infected children with chronically-evolving hepatitis. Arch Virol 1993;8(Suppl.)):237-48.
22. Witzleben CL, Marshall GS, Wenner W, Piccoli DA, Barbour SD. HIV as a cause of giant cell hepatitis. Hum Pathol 1988;19:603-5.
23. Persaud D, Bangaru B, Greco MA et al. Cholestatic hepatitis in children infected with the human immunodeficiency virus. Pediatr Infect Dis J 1993;12:492-8.
24. Miller DR, Hanshaw JB, O’Leary DS, Hnilicka JV. Fatal disseminated herpes simplex virus infection and hemorrhage in the neonate. J Pediatr 1970;76:409-15.
25. Benador N. Mannhardt W, Schranz D et al. Three cases of neonatal herpes simplex infection presenting as fulminant hepatits. Eur J Pediatr 1990;149:555-9.
26. Koskiniemi M, Happonen JM, Jarvenpaa AL et al. Neonatal herpes simplex virus (HSV) infection: a report of 43 patients. Pediatr Infect Dis 1989;8:30-5.
27. Brooks SE, Taylor E, Golden MH, Golden BE. Electron microscopy of herpes simplex hepatitis with hepatocyte pulmonary embolization in kwashiorkor. Arch Pathol Lab Med 1991;115:1247-9.
28. Tomita T, Chiga M, Lenahan M et al. Identification of herpes simplex virus infection by immunoperoxidase and in-situ hybridization methods. Virchows Arch A Pathol Anat Histopathol 1991;419:99-105.
29. de Ville de Goyet J, Kelly DA, Lee WS, McKiernan PJ, Ramani P, Tanner MS. Neonatal liver transplant for fulminant hepatitis caused by Herpes Simplex Virus Type 2. J Pediatr Gastroenterol Nutr 2002;35:220-3.
30. Modlin JF, Kinney JS. Perinatal echovirus infection: insights from a literature review of 61 cases and 16 outbreaks in nurseries. Rev Infect Dis 1986;8:918-26.
31. Chou LL, Chang P, Wu LC. Neonatal coxsackievirus B1 infection associated with severe hepatitis: report of three cases. Acta Paediatr Sin 1995;36:296-9.
32. Kaul A, Cohen ME, Broffman G et al. Reye-like syndrome associated with Coxsackie B2 virus infection. J Pediatr 1979;94:67-9.
33. Koneru B, Jaffe R, Esquivel CO et al. Adenovirus infections in pediatric liver transplant recipients. JAMA 1987;258:489-92.
34. Krilov LR, Rubin LG, Frogel M et al. Disseminated adenovirus infection with hepatic necrosis in patients with human immunodeficiency virus infection and other immunodeficiency states. Rev Infect Dis 1990;12:303-7.
35. Abzug MJ, Lekin MJ. Neonatal adenovirus infection: four patients and review of the literature. Pediatrics 1991;87:890-6.
36. Hicks J, Barrish J, Zhu SH. Neonatal syncytial giant cell hepatitis with paramyxoviral-like inclusions. Ultrastruct Pathol 2001;25: 65-71.
37. Roberts E, Ford-Jones EL, Phillips MJ. Ribavirin for Syncytial Giant Cell Hepatitis. Lancet 1993;341:640-1.
38. Prince AM, Brotman B, Richardson L et al. Incidence of hepatitis A virus infection in rural Liberia. J Med Virol 1985;15:421-8.
39. Amesty-Valbuena A, Gonzalez-Pirela Y, Rivero M. Seroepidemiologic study of hepatitis A virus among children of Maracaibo, Venezuela. Invest Clin 1989;30:215-28.
40. Arkankalle VA, Tsarev SA, Shada MS et al. Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992. J Infect Dis 1995;171:447-50.
41. Innis BI, Snitbhan R, Kunasol P et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1134-8.
42. Yong P. Epidemiology of hepatitis A. Proceedings of the Satellite Symposium of the IX Asian-Pacific Congress of Gastroenterology and the VI Asian-Pacific Congress of Digestive Endoscopy, Bangkok, Thailand, 1992:8.
43. Chin KP, Lok AS, Wong LS et al. Current seroepidemiology of hepatitis A in Hong Kong. J Med Virol 1991;34:191-3.
44. Gay NJ, Morgan-Capner P, Wright J et al. Age-specific antibody prevalence to hepatitis A in England: implications for disease control. Epidemiol Infect 1994;113:113-20.
45. Gust ID, Feinstone SM. Epidemiology of Hepatitis A. Boca Raton:CRC Press, 1988:163-91.
46. Hadler SC, McFarland L. I Hepatitis in day care centers: epidemiology and prevention. Rev Infect Dis 1986;8:548-57.
47. Shimizu H, Takebayashi T, Goto M, Togashi T. Studies on an outbreak of hepatitis A in an institution for mentally retarded children. Hokkaido Igaku Zasshi 1984;59:247-53.
48. Mannucci P, Gdovin S, Gringeri A et al. Transmission of hepatitis A to patients with haemophilia by factor VIII concentrate treated with organic solvent and detergent to inactivate viruses. Ann Intern Med 1994;20:1-7.
49. Watson J, Fleming D, Borella A et al. Vertical transmission of hepatitis A resulting in an outbreak in a neonatal intensive care unit. J Infect Dis 1993;167:567-71.
50. Ye JY. Outcome of pregnancy complicated by hepatitis A in the urban districts of Shanghai. Chung Hua Fu Chan Ko Tsa Chih 1990;25:219-21.
51. Hadler SC, Webster HM, Erben JJ et al. Hepatitis A in day care centers: a community wide assessment. N Engl J Med 1980;302:1222-7.
52. Sun YD, Zhang YC, Ren YH, Meng ZD. Clinical/subclinical case ratio in hepatitis A. Lancet 1988;ii:1082-3.
53. Stuart JM, Majeed FA, Cartwright KAV et al. Salivary antibody testing in a school outbreak of hepatitis A. Epidemiol Infect 1992;109:161-6.
54. Chow CB, Lau TY, Leung NK, Chang WK. Acute viral hepatitis:aetiology and evolution. Arch Dis Child 1989;64:211-13.
55. Hermier M, Descos B, Collet JP et al. Acute cholecystitis disclosing A virus hepatitis. Arch French Pediatr 1985;42:525-9.
56. Toppet V, Souayah H, Delplace O et al. Lymph node enlargement as a sign of acute hepatitis A in children. Pediatr Radiol 1990;20:249-52.
57. McNeill M, Hoy JF, Richards MJ et al. Aetiology of fatal viral hepatitis in Melbourne: a retrospective study. Med J Aust 1984;141:637-40.
58. O’Grady JG, Gimson AES, O’Brien CJ et al. Controlled trial of charcoal haemoperfusion and prognostic indicators in fulminant hepatitic failure. Gastroenterology 1988;94:1186-92.
59. Fishman LN, Jonas MM, Lavine JE. Update on viral hepatitis in children. Pediatr Clin North Am 1996;43:57-74.
60. Chiriaco P, Guadalupi C, Armigliato M et al. Polyphasic course of hepatitis A in children. J Infect Dis 1986;153:378-9.
61. Sjögren MH, Tanno H, Fay O et al. Hepatitis A virus in stool during clinical relapse. Ann Intern Med 1987;106:221-6.
62. Van Damme P, Thoelen S, Cramm M. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity and long-term antibody persistence. J Med Virol 1994;44:446-51.
63. Van Damme P, Banatvala J, Fay O et al. International Consensus Group on Hepatitis A Virus Immunity. Hepatitis A booster vaccination: is there a need? Lancet 2003;362:1065-71.
64. Prikazsky V, Oléar V, Cernoch A et al. Interruption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol 1994;44:457-9.
65. Kiire CF. Hepatitis B infection in sub-Saharan Africa. The African Regional Study Group. Vaccine 1990;8:S107-S112.
66. Beasley RP, Hwang LY, Lin CC et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982;142:198-204.
67. Stroffolini T, Franco E, Romano G et al. Hepatitis B virus infection in children in Sardinia, Italy. Eur J Epidemiol 1989;5:202-6.
68. Tong MJ, Nair PV, Thursby M, Schweitzer IL. Prevention of hepatitis B infection by hepatitis B immunoglobulin in infants born to mothers with acute hepatitis during pregnancy. Gastroenterology 1985;89:160-4.
69. Towers CV, Asrat T, Rumney P. The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood. Am J Obstet Gynecol 2001;184:1514-18.
70. Vranckx R, Alisjahbana A, Meheus A. Hepatitis B virus vaccination and antenatal transmission of HBV markers to neonates. J Viral Hepat 1999;6:135-9.
71. Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow-up study J Pediatr 1998;133:374-7.
72. Wheeley SM, Boxall EH, Tarlow MJ et al. Hepatitis B vaccine in the prevention of perinatally transmitted hepatitis B virus infection: final report on a West Midlands pilot study. J Med Virol 1990;30:113-16.
73. Beath SV, Boxall EH, Watson RM, Tarlow MJ, Kelly DA. Fulminant hepatitis B in infants born to anti-HBe hepatitis B carrier mothers. BMJ 1992;304:1169-70.
74. Ewing CI, Davidson DC. Fatal hepatitis B in infant born to a HBsAg carrier with HbeAb. Arch Dis Child 1985;60:265-7.
75. Sinatra FR, Shah P, Weissman JY, Thomas DW, Merritt RJ, Tong MJ. Perinatal transmitted acute icteric hepatitis B in infants born to hepatitis B surface antigen-positive and anti-hepatitis Be-positive carrier mothers. Pediatrics 1982;70:557-9.
76. Ferreira GC, Veiga M, Po I, Curvelo A, Rodrigues O, Espinosa L. Fulminant hepatitis in a newborn infant whose mother was a carrier of the hepatitis B surface antigen and e antibody. Helv Paediatr Acta 1987;42:41-4.
77. Stevens CE, Neurath RE, Beasley RP, Szmuness W. HBsAg and anti-HBe detection by radioimmunoassay: correlation of vertical transmission of hepatitis B virus in Taiwan. J Med Virol 1979;3:237-41.
78. Draelos KZ, Hansen RC, James MAJ. Gianotti Crosti syndrome associated with infections other than hepatitis B. JAMA 1986;256:2386-8.
79. Caporaso N, Coltorti M, Del Vecchio-Blanco C et al. Acute viral hepatitis in childhood: etiology and evolution. J Pediatr Gastroenterol Nutr 1983;2:99-104.
80. Farci P, Barbera C, Navone C et al. Infection with the delta agent in children. Gut 1985;26:4-7.
81. von Weirsacker F, Pult I, Geiss K et al. Selective transmission of variant genome from mother to infant in neonatal fulminant hepatitis B. Hepatology 1995;21:8-13.
82. Hawkins AE, Gilson RJ, Beath SV et al. Novel application of a point mutation assay: evidence for transmission of hepatitis B viruses with precore mutations and their detection in infants with fulminant hepatitis B. J Med Virol 1994;44:13-21.
83. Lok ASF, Kwan WK, Moeckli R et al. Seroepidemiological survey of hepatitis E in Hong Kong by recombinant-based enzyme immunoassays. Lancet 1992;340:1205-8.
84. Lee SD, Wang YJ, Lu RW et al. Seroprevalence of antibody to hepatitis E virus among Chinese subjects in Taiwan. Hepatology 1994;19:866-70.
85. Hyams KC, Purdy MA, Kaur M et al. Acute sporadic hepatitis E in Sudanese children: analysis based on a new Western blot assay. J Infect Dis 1992;165:1001-5.
86. Bradley DW Enterically-transmitted non-A, non-B hepatitis. Br Med Bull 1990;46:442-61.
87. Khuroo MS, Kamili S, Jameel S. Vertical transmission of hepatitis E virus. Lancet 1995;45:1025-6.
88. Hamid SS, Atiq M, Shehzad F et al. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 2002;36:474-8.
89. Favorov MO, Fields HA, Purdy MA et al. Serologic identification of hepatitis E virus infections in epidemic and endemic settings. J Med Virol 1992;36:246-50.
90. Li TC, Suzaki Y, Ami Y, Dhole TN, Miyamura T, Takeda N. Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. Vaccine 2004;22:370-7.
91. Tsarev SA, Tsareva TS, Emerson SU et al. Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge. Vaccine 1997;15:1834-8.
92. Purcell RH, Nguyen H, Shapiro M et al. Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine 2003;21:2607-15.
93. Fagan EA, Ellis DS, Tovey GM et al. Toga-like virus as a cause of fulminant hepatitis attributed to sporadic non-A, non-B. J Med Virol 1998;28:150-5.
94. Fagan EA, Ellis DS, Tovey GM et al. Toga virus-like particles in acute liver failure attributed to sporadic non-A, non-B hepatitis and recurrence after liver transplantation. J Med Virol 1992;38:71-7.
95. Linnen J, Wages J Jr, Zhang-Keck ZY et al. Molecular cloning and disease association of hepatitis G virus: a transfusiontransmissible agent. Science 1996;271:505-8.
96. Alter HJ. Cloning and clinical implications of HGV and HGBVC. N Engl J Med 1996;334:1536-7.
97. Lin HH, Kao JH, Chen PJ, Chen DS. Mechanism of vertical transmission of hepatitis G (letter). Lancet 1996;347:1116.
98. Cheng PN, Chang TT, Jen CM, Ko AW, Young KC, Wu HL. Molecular evidence for transmission of GB virus-C/hepatitis G virus infection within family: close relationship between mother and child. Hepatogastroenterology 2003;50:151-6.
99. Wejstal R, Manson AS, Widell A, Norkrans G. Perinatal transmission of hepatitis G virus (GB virus type C) and hepatitis C virus infections - a comparison. Clin Infect Dis 1999;28:816-21.
100. Palomba E, Bairo A, Tovo PA. High rate of maternal-infant transmission of hepatitis G virus in HIV-1 and hepatitis C virus- infected women. Acta Paediatr 1999;88:1392-5.
101. Schroter M, Polywka S, Zollner B, Schafer P, Laufs R, Feucht HH. Detection of TT virus DNA and GB virus type C/hepatitis G virus RNA in serum and breast milk: determination of mother-to-child transmission. J Clin Microbiol 2000;38:745-7.
102. Minola E, Berera F, Fracassetti O, Quinzan G, Lorenzi N, Del Vecchio G. Evolution of hepatitis G in children with vertically transmitted HGV. Infez Med 2000;1:30-3.
103. Davison SM, Skidmore SJ, Collingham KE, Irving WL, Hubscher SG, Kelly DA. Chronic hepatitis in children after liver transplantation: role of hepatitis C virus and hepatitis G virus infections. J Hepatol 1998;28:764-70.
104. Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997;241:92-7.
105. Sottini A, Mattioli S, Fiordalisi G, Imberti L, Moratto D, Primi D (2002). Molecular and biological characterisation of SEN viruses:a family of viruses remotely related to the original TTV isolates. In: Margolis HS, Alter MJ, Liang TJ, Deinstag JL, eds. Proceedings of the 10th International Symposium on Viral Hepatitis and Liver Disease. Atlanta, GA International Medical Press.
106. Lin HH, Kao JH, Lee PI, Chen DS. Early acquisition of TT virus in infants: possible minor role of maternal transmission. J Med Virol 2002;66:285-90.
107. Pirovano S, Bellinzoni M, Ballerini C et al. Transmission of SEN virus from mothers to their babies. J Med Virol 2002;66:421-7.
108. Tzakis AG, Arditi M, Whitington PF et al. Aplastic anaemia complicating orthotopic liver transplantation for non-A, non-B hepatitis. N Engl J Med 1988;319:393-6.
109. Tung J, Hadzic N, Layton M et al. Bone marrow failure in children with acute liver failure. J Paediatr Gastroenterol Nutr 2000;31:557-61.
110. Shalev-Zimels H, Weizman Z, Lotan C et al. Extent of measles hepatitis in various ages. Hepatology 1988;8:1138-9.
111. Makhene MK, Diaz PS. Clinical presentation and complications of suspected measles in hospitalised children. Pediatr Infect Dis J 1993;12:836-40.
112. Khatib R, Siddique M, Abbass M. Measles associated hepatobiliary disease: an overview. Infection 1993;21:112-14.
113. Vento S, Cainelli F, Ferraro T, Concia E. Autoimmune hepatitis type 1 after measles. Am J Gastroenterol 1996;91:2618-20.
114. Tsai WS, Chang MH, Chen JY et al. Seroepidemiological study of Epstein-Barr infection in children in Taipei. Acta Paediatr Sin 1989;30:81-6.
115. Kahn E, Greco A, Daum F et al. Hepatic pathology in pediatric acquired immunodeficiency syndrome. Hum Pathol 1991;22:1111-19.
116. Chen RL, Su IJ, Lin KH et al. Fulminant childhood hemophagocytic syndrome mimicking histiocytic medullary reticulosis. An atypical form of Epstein-Barr virus infection. Am J Clin Pathol 1991;96:171-6.
117. Giller RH, Grose C. Epstein-Barr virus: the hematologic and oncologic consequences of virus-host interaction. Crit Rev Oncol Hematol 1989;9:149-95.
118. Purtilo DT. Epstein-Barr virus: the spectrum of its manifestations in human beings. South Med J 1987;80:943-7.
119. Tanaka K, Shimada M, Sasahara A et al. Chronic hepatitis associated with Epstein-Barr virus infection in an infant. J Pediatr Gastroenterol Nutr 1984;5:467-71.
120. Anderson JP. Clinical aspects of Epstein-Barr virus infection. Scand J Infect Dis 1991;80(Suppl.)):90-104.
121. Haque T, Wilkie GM, Taylor C et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002;360:436-42.
122. Lones MA, Mishalani S, Shintaku IP et al. Changes in tonsils and adenoids in children with posttransplant lymphoproliferative disorder: report of three cases of early involvement of Waldeyer’s ring. Hum Pathol 1995;26:525-30.
123. Kimberlin DW. Human herpesviruses 6 and 7: identification of newly recognized viral pathogens and their association with human disease. Pediatr Infect Dis J 1998;17: 59-68.
124. Asano Y, Yoshikawa T, Suja S et al. Fatal fulminant hepatitis in an infant with human herpes virus-6 infection. Lancet 1990;335:862-3.
125. McGregor SR, Zitelli BJ, Urbach AH et al. Varicella in pediatric orthotopic liver transplant recipients. Pediatrics 1989;83:256-61.
126. Leibovitz E, Cooper D, Giurgiutiu D et al. Varicella-zoster virus infection in Romanian children infected with the human immunodeficiency virus. Pediatrics 1993;91:838-42.
127. Nigro G, Scholz H, Bartmann U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants:a two-regimen experience. J Pediatr 1994;124:318-22.
128. Jonas MM, Roldan EO, Lyons HJ et al. Histopathologic features of the liver in acquired immunodeficiency syndrome. J Pediatr Gastroenterol Nutr 1989;9:73-6.
129. Mok JYQ, Hague RA, Yap PL et al. Vertical transmission of HIV: a prospective study. Arch Dis Child 1989;64:1140-5.
130. Alvarez ME, Ramirez-Ronda CH. Dengue and hepatic failure. Am J Med 1985;79:670-4.
131. George R, Liam CK, Chua CT et al. Unusual clinical manifestations of dengue virus infection. Southeast Asian J Trop Med Public Health 1988;19:585-90.
132. Cunha BA. Systemic infections affecting the liver. Some cause jaundice, some do not. Postgrad Med 1988;84:148-158 253.
133. Monath TP, Nystrom RR. Detection of yellow fever virus in serum by enzyme linked immunoassay. Am J Trop Med Hyg 1984;33:151-7.
134. Price ME, Fisher-Hoch SP, Craven RB, McCormick JB. A prospective study of maternal and foetal outcome in acute Lassa fever infection during pregnancy. BMJ 1988;297:584-7.
135. de Cock KM, Monath TP, Nasidi A et al. Epidemic yellow fever in Eastern Nigeria, 1986. Lancet 1988;i:630-2.
136. McCormick JB, Walker DH, King IJ et al. Lassa virus hepatitis:a study of fatal Lassa fever in humans. Am J Trop Med Hyg 1986;35:401-7.
137. Snell N. Ribavirin therapy for Lassa fever. Practitioner 1988;232:432.
138. Williams R, Riordan SM. Acute liver failure: established and putative hepatitis viruses and therapeutic implications. J Gastroenterol Hepatol 2000;15:17-25.
139. Whitington PF, Alonso EM. Fulminant Hepatitis and Acute Liver Failure. Diseases of the Liver and Biliary System. Blackwell Publishing, Oxford 2003:107-26.
140. Chada MS, Walimbe AM, Chobe LP, Arankalle VA. Comparison of etiology of sporadic acute and fulminant viral hepatitis in hospitalized patients in Pune, India during 1978-81 and 1994-97. Indian J Gastroenterol 2003;22:11-15.
141. Debray DP, Cullufi D, Devictor M, Fabre, Bernard O. Liver failure in children with hepatitis A. Hepatology 1997;26:1018-22.
142. Chang MH, Lee CY, Chen DS, Hsu HC, Lai MY. Fulminant hepatitis in children in Taiwan: the important role of hepatitis B virus. J Pediatr 1986;3:34-8.
143. Chen PM, Chiou TJ, Fan FS et al. Fulminant hepatitis is significantly increased in hepatitis B carriers after allogenic bone marrow transplantation. Transplantation 1999;67:1425-3.
144. Farci P, Alter HJ, Shimoda A et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996;335:631-4.
145. Gimson AES, White YS, Eddleston WF, Williams R. Clinical and prognostic differences in fulminant hepatitis type A, B and non-A, non-B. Gut 1983;24:1194-8
146. Salt A, Sutehall G, Sargaison M et al. Viral and Toxoplasma gondii infections in children after liver transplantation. J Clin Pathol 1990;43:63-7.
147. Stratta RJ, Shaeffer MS, Cushing KA et al. Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients. Transplantation 1991;51:90-7.
148. Shaefer MS, Stratta RJ, Markin RS et al. Ganciclovir therapy for cytomegalovirus disease in liver transplant recipients. Transplant Proc 1991;23:1515-16.
149. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R. An increased incidence of EpsteinBarr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995;59:524-9.
150. Alero Thomas J, Burke M, Hadzic D et al. Immunodeficiencyrelated lymphoproliferative disorders: prospective date from the UK Children’s Cancer Study Group Registry. Br J Haematol 2002;118:456-61.
151. Michaels MG, Green M, Wald ER, Starzl TE. Adenovirus infection in pediatric liver transplant recipients. J Infect Dis 1992;165:170-4.
152. Hsu HY, Chang MH, Hsieh KH et al. Cellular immune response to HBsAg in mother-to-infant transmission of hepatitis B virus. Hepatology 1992;15:770-6.
153. Maggiore G, De Giacomo C, Marzani D et al. Chronic viral hepatitis B in infancy. J Pediatr 1983;103:749-52.
154. Boxall EH, Sira J, Sleight E et al. The natural history of hepatitis B in perinatally infected carriers. Arch Dis Child Fetal Neonatal Ed 2004;89:F456-60.
155. Hsu HC, Lin YH, Chang MH et al. Pathology of chronic hepatitis B virus infection in children with special reference to the intrahepatic expression of hepatitis virus antigens. Hepatology 1988;8:378-82.
156. Bortolotti F, Calzia R, Cadrobbi P et al. Liver cirrhosis associated with chronic hepatitis B virus infection in childhood. J Pediatr 1986;198:224-7.
157. Hsu HC, Wu MZ, Chang MJ et al. Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan: a report of 51 cases strongly associated with rapid development of liver cirrhosis. J Hepatol 1987;5:260-7.
158. Leuschner I, Harms D, Schmidt D. The association of hepatocellular carcinoma in childhood with hepatitis B virus infection. Cancer 1988;62:2363-9.
159. de Potter CR, Robberecht E, Laureys G, Cuvelier CA. Hepatitis B related childhood hepatocellular carcinoma. Cancer 1987;60:414-18.
160. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977;105:94-8.
161. Wang Z, Zhang J, Yang H et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003;71:360-6.
162. Alexander JM, Ramus R, Jackson G, Sercely B, Wendel GD Jr. Risk of hepatitis B transmission after amniocentesis in chronic hepatitis B carriers. Infect Dis Obstet Gynecol 1999;7:283-6.
163. Wang J, Zhu Q, Zhang X. Effect of delivery mode on maternalinfant transmission of hepatitis B virus by immunoprophylaxis. Chin Med J (Engl) 2002;115:1510-12.
164. Lin HH, Kao JH, Hsu HY, Mizokami M, Hirano K, Chen DS. Least microtransfusion from mother to fetus in elective cesarean delivery. Obstet Gynecol 1996;87:244-8.
165. Xu DZ, Yan YP, Choi BC et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002;67:20-6.
166. Xu DZ, Yan YP, Zou S et al. Role of placental tissues in the intrauterine transmission of hepatitis B virus. Am J Obstet Gynecol 2001;185:981-7.
167. Boxall EH, Derso A, Flewett TH. Breast feeding in hepatitis B carrier mothers. In: Freier S, Eidelman AJ, eds. Human Milk - Its Biological and Social Value. Amsterdam: Excerpta Medica, 1980.
168. Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers Obstet Gynecol 2002;99:1049-52.
169. Chang MH, Hsu HY, Huang LM, Lee PI, Lin HH, Lee CY. The role of transplacental hepatitis B core antibody in the mother-to-infant transmission of hepatitis B virus. J Hepatol 1996;24:674-9.
170. Milich DR. Immune response to hepatitis B proteins: relevance of the murine model. Semin Liver Dis 1991;11:93-112.
171. Milich DR, Jones J, Hughes J, Maruyama T. Role of T-cell tolerance in the persistence of hepatitis B virus infection. J Immunother 1993;14:226-33.
172. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990;87:6599-603.
173. Boxall EH, Flewett TH, Derso A, Tarlow MJ. Specific immunoglobulin for babies born to HBsAg carriers. Lancet 1980;1:419-20.
174. Beasley RP, Hwang LY, Szmuness W et al. HBIG prophylaxis for perinatal HBV infections - final report of the Taiwan trial. Dev Biol Stand 1983;54:363-75.
175. Wong VC, Ip HM, Reesink HW et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1984;1:921-6.
176. Pongpipat D, Suvatte V, Assateerawatts A. Vaccination against hepatitis B virus infection in neonates. Helv Paediatr Acta 1984;39:231-6.
177. Tsen YJ, Chang MJ, Hsu HY et al. Seroprevalence of hepatitis B virus infection in children in Taipei, 1989: five years after a mass hepatitis B vaccination program. J Med Virol 1991;34:96-9.
178. Poovorawan Y, Sanpavat S, Pongpunlert W et al. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen positive mothers. JAMA 1989;261:3278-81.
179. Whittle HC, Maine N, Pilkington J et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995;345:1089-92.
180. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
181. Marion SA, Pastore MT, Pi DW, Mathias RG. Long-term follow- up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 1994;140:734-46.
182. Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J 2003;22:157-63.
183. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study. J Infect Dis 1997;175:674-7.
184. Wu JS, Hwang L-Y, Goodman KJ, Palmer Beasley R. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis 1999;179:1319-25.
185. Whittle H, Jaffar S, Wansbrough M et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002;325:569.
186. Chong-Jin O, Wei Ning C, Shiuan K, Gek Keow L. Identification of hepatitis B surface antigen variants with alterations outside the ‘a’ determinant in immunized Singapore infants. J Infect Dis 1999;179:259-63.
187. Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999;30:1312-17.
188. Wilson JN, Nokes DJ, Carman WF. Predictions of the emergence of vaccine-resistant hepatitis B in the Gambia using a mathematical model. Epidemiol Infect 2000;124:295-307.
189. Connor EM, Sperling RS, Gelber R et al. Reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
190. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10:294-7.
191. Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet 2002;359:1488-9.
192. Merican I. Management of chronic hepatitis B. Treatment of chronic hepatitis B virus infection in special groups of patients:decompensated cirrhosis, immunosuppressed and paediatric patients. J Gastroenterol Hepatol 2000;15:E71-E78.
193. Ruiz-Moreno M, Rua MJ, Molina J et al. Prospective randomized controlled trial of interferon-α in children with chronic hepatitis B. Hepatology 1991;13:1035-9.
194. Lai CL, Wong B, Yeoh EK et al. Five-year follow-up of a prospective randomised trial of hepatitis B recombinant DNA yeast vaccine vs plasma-derived vaccine in children: immunogenicity and anamnestic response. Hepatology 1993;18:763-7.
195. Kelly D, Sira J, Lloyd C, Davies P. Interferon treatment enhances seroconversion in vertically HBV infected children. Hepatology 2001;34:624A.
196. Mellerup MT, Krogsgaard K, Mathurin P, Gluud C, Poynard T. Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B (Cochrane Review). Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, 2004.
197. Jara P, Bortolotti F. Interferon-(alpha) treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr 1999;29:163-70.
198. Malik AH, Lee WM. Chronic hepatitis B virus infection:treatment strategies for the next millenium. Ann Intern Med 2000;132:723-31.
199. Farrell G. Hepatitis B e Antigen seroconversion: effects of lamivudine alone or in combination with interferon alpha. J Med Virol 2000;61:374-9.
200. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999;30:770-4.
201. Jonas MM, Kelly DA, Mizerski J et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13.
202. Leung N. Liver disease - significant improvement with lamivudine. J Med Virol 2000;61:380-5.
203. Sokal EM, Roberts EA, Mieli-Vergani G, McPhillips P, Johnson M. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adults with chronic hepatitis B. Antimicrob Agents Chemother 2000;44:590-7.
204. Yakin K, Degertekin H, Yildiz F, Celik Y. Comparison of 12- month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alph-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis 2003;36:1516-22.
205. Bahar A, Iscan S, Karademir F, Gocmen I. Efficacy of interferon alpha-2b and lamivudine therapy for chronic hepatitis B in children. Chin Med J (Engl) 2003;16:593-6.
206. Calio R, Villani E, Balestra E et al. Enhancement of natural killer activity and interferon induction by different cyclic nucleoside phosphonates. Antiviral Res 1994;23:77-89.
207. Gibb DM, Neave PE, Tookey PA. Active surveillance of hepatitis C infection in the UK and Ireland. Arch Dis Child 2000;82:286-91.
208. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:1192.
209. Vo Thi Diem H, Bourgois A, Govens P, Bontems P, Buts JP, Sokal E. Natural and treatment related history of chronic hepatitis B virus infection. A long term follow up study in 158 children. J Pediatr Gastroenterol Nutr 2002;34:A10.
210. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management. Rev Med Virol 2001;11:287-99.
211. Saif MW, Little RF, Hamilton JM, Allegra CJ, Wilson WH. Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature. Ann Oncol 2001;12:123-9.
212. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-13.
213. Brechot C, Bernuau J, Thiers V et al. Multiplication of hepatitis B virus in fulminant hepatitis B. BMJ 1984;288:270-1.
214. Wreghitt TG, Gray JJ, Allain J-P et al. Transmission of hepatitis C virus by organ transplantation in the United Kingdom. J Hepatol 1994;20:768-72.
215. Tillmann HL, Manns MP. Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups. Dig Dis Sci 1996;41:27S-40S.
216. Tedder RS, Briggs M, Ring C et al. Hepatitis C antibody profile and viraemia prevalence in adults with severe haemophilia. Br J Haematol 1991;79:512-15.
217. Menozzi D, Udulutch T, Llosa AE, Galel SA. HCV lookback in the United States: effectiveness of an extended lookback program. Transfusion 2000;40:1393-8.
218. Transfusion transmission of HCV infection before anti-HCV testing of blood donations in England: results of the national HCV lookback program. Transfusion 2002;42:1146-53.
219. Tobler LH, Tegtmeier G, Stramer SL et al. Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays: justification and rational implementation. Transfusion 2000;40:15-24.
220. Bortolotti F, Iorio R, Resti M et al. An epidemiological survey of hepatitis C virus infection in Italian children in the decade 1990-1999. J Paediatr Gastroenterol Nutr 2001;32:562-6.
221. Ngatchu T, Stroffolini T, Rapicetta M et al. Seroprevalence of anti-HCV in an urban child population: a pilot survey in a developing area, Cameroon. J Trop Med Hyg 1992;95:57-61.
222. Al-Faleh FZ, Ayoola EA, Al-Jeffry M et al. Prevalence of antibody to hepatitis C virus among Saudi Arabian children: a community-based study. Hepatology 1991;14:215-18.
223. Resti M, Azzari C, Rossi ME et al. Hepatitis C virus antibodies in a long-term follow-up of beta-thalassaemic children with acute and chronic non-A non-B hepatitis. Eur J Pediatr 1992;151:573-6.
224. Blanchette VS, Vortsman E, Shore A et al. Hepatitis C infection in children with hemophilia A and B. Blood 1991;78:285-9.
225. Jonas MM, Zilleruelo GE, La Rue SI et al. Hepatitis C infection in a pediatric dialysis population. Pediatrics 1992;89:707-9.
226. Locasciulli A, Gornati G, Tagger A et al. Hepatitis C virus infection and chronic liver disease in children with leukemia in long term remission. Blood 1991;78:1619-22.
227. Fink FM, Hocker-Schulz S, Mor W et al. Association of hepatitis C virus infection with chronic liver disease in paediatric cancer patients. Eur J Pediatr 1993;152:490-2.
228. Ruiz-Extemera A, Salmeron J, Torres C et al. Follow-up of transmission of hepatitis C to babies of human immunodeficiency virus-negative women: the role of breast-feeding in transmission. Pediatr Infect Dis J 2000;19:511-16.
229. Bortolotti F, Vajro P, Cardrobbi P et al. Cryptogenic chronic liver disease and hepatitis C virus infection in children. J Hepatol 1992;15:73-6.
230. Ding-Shinn C, Kuo GC, Juei-Low S et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1991;162:817-22.
231. Ades AE, Parker S, Walker J, Cubitt WD, Jones R. HCV prevalence in pregnant women in the UK. Epidemiol Infect 2000;125:399-405.
232. Gibb DM, Goodall RL, Dunn DT et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2002b;356:904-7.
233. Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998;27:108-17.
234. Ohto H, Terazawa S, Sasaki N et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994;330:744-50.
235. Tovo PA, Palombo E, Ferraris G et al. Increased risk of maternal- infant hepatitis C virus transmission for women co-infected with human immunodeficiency virus type 1. Clin Infect Dis 1997;25:1121-4.
236. Resti M, Azzari C, Mannelli F et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. BMJ 1998;317:437-41.
237. European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-tochild transmission of hepatitis C virus. BJOG 2001:108:371-7.
238. Dunn DT, Gibb DM, Healy M et al. Timing and interpretation of tests for diagnosing perinatally acquired hepatitis C virus infection. Pediatr Infect Dis J 2001;20:715-16.
239. Ceci O, Margiotta M, Marello F. Vertical transmission of hepatitis C virus in a cohort of 2, 477 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr 2001;33:570-5.
240. Bortolotti F, Jara P, Diaz C et al. Posttransfusion and community- acquired hepatitis C in childhood. J Pediatr Gastroenterol Nutr 1994;18:279-83.
241. Sira J, Bunn SK, Kelly DA. Paediatric hepatitis C - a single centre experience. Abstract - late breaker session: 11th International Symposium on Viral Hepatitis and Liver Disease, Sydney, Australia, April 2003.
242. Birnbaum AH, Shneider BL, Moy L. Hepatitis C in children. N Engl J Med 2000;342:290-1.
243. Badizadegan K, Jonas MM, Ott JJ et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998;28:1416-23.
244. Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002;34:52-8.
245. Kjaergard LL, Krogsgaard K, Gluud C. Ribavirin with or without alpha interferon for chronic hepatitis C. Cochrane Database Syst Rev 2002;(2):CD002234.
246. Kelly DA, Bunn S, Apelian D et al. Safety, efficacy and pharmacokinetics of interferon alfa 2B plus ribavirin in children with chronic hepatitis C. Hepatology 2001;34:342A.
247. Suoglu D, Elkabes B, Sokucu S, Saner G. Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C? J Pediatr Gastroenterol Nutr 2002;34:199-206.
248. Lackner H, Moser A, Deutsch J et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000;106:E53.
249. Glue P, Rouzier-Panis R, Raffanel C et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000;32:647-53.
250. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
251. Schwarz KB, Mohan P, Narkewicz M et al. The safety, effi- cacy and pharmacokinetics of Peginterferon alfa-2a (40KD) (Pegasys®) in children with chronic hepatitis C. Digestive Disease Weekly 2003;15:Abstract.
252. Bensabath G, Hadler SC, Soares MC et al. Hepatitis delta virus infection and Labrea hepatitis. Prevalence and role in fulminant hepatitis in the Amazon Basin. JAMA 1987;258:479-83.
253. Bonino F, Caporaso N, Dentico P et al. Familial clustering and spreading of hepatitis delta virus infection. J Hepatol 1985;1:221-6.
254. Hadler SC, Alcala de Monzon M, Rivero D et al. Epidemiology and long-term consequences of hepatitis delta virus infection in the Yucpa Indians of Venezuela. Am J Epidemiol 1992;136:1507-16.
255. Hsu HY, Chang MH, Chen DS, Lee CY. Hepatitis D virus infection in children with acute or chronic hepatitis B virus infection in Taiwan. J Pediatr 1988;112:888-92.
256. Chen GH, Zhang MD, Huang W. Hepatitis delta virus superinfection in Guangzhou area. Chin Med J 1990;103:451-4.
257. Rossetti F, Zancan L, Bonato G et al. Delta virus and childhood leukemia. Pediatr Hematol Oncol 1991;8:23-32.
258. Buitrago B, Hadler SC, Popper H et al. Epidemiologic aspects of Santa Marta hepatitis over a 40-year period. Hepatology 1986;6:1292-6.
259. Kay MH, Wyllie R, Deimler C et al. Alpha interferon therapy in children with chronic active hepatitis B and delta virus infection. J Pediatr 1983;123:1001-4.